Takaku Reo, Yokoyama Izumi
Graduate School of Economics, Hitotsubashi University, 2-1, Naka, Kunitachi, Tokyo 186-8601, Japan.
J Jpn Int Econ. 2022 Sep;65:101218. doi: 10.1016/j.jjie.2022.101218. Epub 2022 Jul 29.
The hospitals in Japan have hitherto had complete autonomy in deciding whether to admit COVID-19 patients. In fact, they were "swinging" between admitting or not COVID-19 patients, especially during the initial COVID-19 outbreak. To address endogenous decision making, we estimated the effect of admitting COVID-19 patients on hospital profits using instrumental variable (IV) regression. We derived the IVs from the guidelines of the national government on which hospital types should admit COVID-19 patients. Our empirical results revealed that the monthly profits per bed decreased by approximately JPY 600,000 ( USD 4615), which is 15 times the average monthly profit in 2019. This overwhelming financial damage indicates it is costly for some hospitals to treat COVID-19 patients because of their low suitability in admitting such patients. Based on the implications of our main results, we propose an alternative strategy to handling patient surges in case of new infectious disease outbreaks.
迄今为止,日本的医院在决定是否收治新冠肺炎患者方面拥有完全自主权。事实上,它们在收治或不收治新冠肺炎患者之间“摇摆不定”,尤其是在新冠肺炎疫情初期。为了解决内生性决策问题,我们使用工具变量(IV)回归估计了收治新冠肺炎患者对医院利润的影响。我们从国家政府关于哪些类型的医院应该收治新冠肺炎患者的指导方针中得出工具变量。我们的实证结果显示,每张病床的月利润减少了约60万日元(4615美元),这是2019年月平均利润的15倍。这种巨大的财务损失表明,对于一些医院来说,治疗新冠肺炎患者成本高昂,因为它们收治此类患者的适用性较低。基于我们主要结果的启示,我们提出了一种在新的传染病爆发时应对患者激增的替代策略。